Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;35(6):e70084.
doi: 10.1111/sms.70084.

Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial

Lauri Rantaniemi  1   2 , Ilkka Jussila  3   4 , Aino Siltari  1   5 , Juha P Ahtiainen  4 , Annastiina Hakulinen  1 , Eeva Harju  6   7   8 , Jorma Sormunen  1   6   9 , Tupu Nordström  10 , Teuvo L J Tammela  1   6 , Teemu J Murtola  1   6
Affiliations
Randomized Controlled Trial

Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial

Lauri Rantaniemi et al. Scand J Med Sci Sports. 2025 Jun.

Abstract

To explore the benefits and safety of supervised and unsupervised exercise among localized and metastatic prostate cancer patients (PCa) during long-term androgen deprivation therapy (ADT). A total of 44 PCa patients were enrolled in this randomized controlled trial (RCT). Participants were randomized in a 1:1 ratio into the supervised exercise sessions group or the unsupervised home-based exercise group for three months. The primary outcomes assessed included quality of life (QoL), body composition, and metabolic markers, which were measured at baseline, after 3 months, and at 6 months. Muscle strength was evaluated exclusively in the supervised exercise group. The main statistical models used were the Mann-Whitney U-test for between-group comparisons and the Wilcoxon rank-sum test for within-group changes. No adverse events were reported during the exercise period. There were no significant differences in QoL, body composition, or metabolic profiles between the intervention and control groups. The supervised exercise group demonstrated significant improvement in emotional functioning (Z = -2.102, p = 0.036) and all exercise performance metrics (p < 0.001), with the most pronounced gains observed in the leg press (Z = -4.17, p < 0.001). Furthermore, a significant association was identified between strength improvements and enhanced self-evaluated physical function (p < 0.001). Supervised exercise is safe for patients with localized and metastatic PCa undergoing ADT and leads to significant improvements in emotional well-being and muscle strength, which translate to better self-reported physical function. Findings underscore the need for RCTs with longer intervention and follow-up periods on supervised exercise, especially in metastatic PCa patients. Trial Registration: ClinicalTrials.gov identifier: #NCT04050397.

Keywords: androgen deprivation therapy; cancer; exercise; metastatic; prostate cancer; quality of life; resistance training; safety.

PubMed Disclaimer

Conflict of interest statement

Teemu J. Murtola: Lecture fees from Astellas, Amgen, Janssen, Novartis, and Sanofi; paid consultant for Astellas, AstraZeneca, Johnson & Johnson, Pfizer, and Accord; clinical trial funding from Bayer, Pfizer, and Janssen. Jorma Sormunen: Lecture fees Johnson & Johnson, Accord.

Figures

FIGURE 1
FIGURE 1
Study flow diagram.
FIGURE 2
FIGURE 2
Exercise regimens for the intervention and control groups.
FIGURE 3
FIGURE 3
Box and whisker plot of the effects of supervised strength training on strength parameters (*p = 0.05; **p < 0.001).
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263, 10.3322/caac.21834. - DOI - PubMed
    1. Litwin M. S. and Tan H. J., “The Diagnosis and Treatment of Prostate Cancer: A Review,” JAMA 317, no. 24 (2017): 2532–2542, 10.1001/jama.2017.7248. - DOI - PubMed
    1. Taylor L. G., Canfield S. E., and Du X. L., “Review of Major Adverse Effects of Androgen‐Deprivation Therapy in Men With Prostate Cancer,” Cancer 115, no. 11 (2009): 2388–2399, 10.1002/cncr.24283. - DOI - PubMed
    1. Nguyen P. L., Alibhai S. M., Basaria S., et al., “Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them,” European Urology 67, no. 5 (2015): 825–836, 10.1016/j.eururo.2014.07.010. - DOI - PubMed
    1. Campbell K. L., Winters‐Stone K. M., Wiskemann J., et al., “Exercise Guidelines for Cancer Survivors: Consensus Statement From International Multidisciplinary Roundtable,” Medicine and Science in Sports and Exercise 51, no. 11 (2019): 2375–2390, 10.1249/MSS.0000000000002116. - DOI - PMC - PubMed

Publication types

Substances

Associated data